The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
出版年份 2015 全文链接
标题
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
作者
关键词
Human Serum Albumin, Tocilizumab, Cynomolgus Monkey, Affinity Maturation, Recombinant Human Serum Albumin
出版物
ARTHRITIS RESEARCH & THERAPY
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-05-21
DOI
10.1186/s13075-015-0651-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
- (2014) J.-B. Holz et al. ANNALS OF THE RHEUMATIC DISEASES
- Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
- (2014) Glynn Dennis et al. ARTHRITIS RESEARCH & THERAPY
- Interleukin 6 and Rheumatoid Arthritis
- (2014) Yuji Yoshida et al. Biomed Research International
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Nanobodies and their potential applications
- (2013) Gholamreza Hassanzadeh-Ghassabeh et al. Nanomedicine
- PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
- (2013) Jacky Woo et al. ARTHRITIS RESEARCH & THERAPY
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Current Understanding of Rheumatoid Arthritis Therapy
- (2012) I Colmegna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
- (2012) E. Choy RHEUMATOLOGY
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis
- (2011) Yoshikuni MIMATA et al. International Journal of Rheumatic Diseases
- XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases
- (2011) Alexander M. Owyang et al. mAbs
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Neonatal Fc Receptor: From Immunity to Therapeutics
- (2010) Timothy T. Kuo et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
- (2010) Nicolas Frey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Unknown
- (2010) Gianfranco Ferraccioli et al. MOLECULAR MEDICINE
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, Ameliorates Joint Swelling in Established Monkey Collagen-Induced Arthritis
- (2008) Yasushi Uchiyama et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
- (2008) N. Nishimoto et al. BLOOD
- The significance of non-human primates as preclinical models of human arthritic disease
- (2008) Michel Vierboom et al. Expert Opinion on Drug Discovery
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started